Improved survival with nivolumab plus ipilimumab in untreated malignant pleural mesothelioma

Two year follow up of the Phase III CheckMate-743 trial, reported 26% reduction in mortality and improved median survival (18.1 vs 14.1months) vs platinum-based standard of care therapy.

Source:

PharmaTimes